CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United ...

Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

The global car-t cell therapy market was valued at USD 5.2 billion in 2024 and is projected to reach USD 26.2 billion by 2030, expected to grow at a CAGR of 31 % during the forecast period, 2025-2030.

Glioblastoma remains one of the most challenging solid tumors to treat due to its highly immunosuppressive tumor microenvironment.

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...